11,535 Shares in Apogee Therapeutics, Inc. (NASDAQ:APGE) Acquired by AQR Capital Management LLC

AQR Capital Management LLC acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 11,535 shares of the company’s stock, valued at approximately $454,000.

Other institutional investors also recently bought and sold shares of the company. Arizona State Retirement System boosted its stake in Apogee Therapeutics by 4.5% during the second quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after buying an additional 258 shares during the last quarter. EntryPoint Capital LLC boosted its position in Apogee Therapeutics by 44.7% during the first quarter. EntryPoint Capital LLC now owns 1,997 shares of the company’s stock valued at $133,000 after purchasing an additional 617 shares in the last quarter. Principal Financial Group Inc. raised its stake in shares of Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after acquiring an additional 1,340 shares in the last quarter. Ameritas Investment Partners Inc. boosted its position in shares of Apogee Therapeutics by 111.2% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,126 shares of the company’s stock worth $274,000 after purchasing an additional 2,172 shares in the last quarter. Finally, American Century Companies Inc. increased its holdings in shares of Apogee Therapeutics by 34.0% during the second quarter. American Century Companies Inc. now owns 8,673 shares of the company’s stock valued at $341,000 after acquiring an additional 2,199 shares in the last quarter. 79.04% of the stock is owned by institutional investors.

Insider Buying and Selling at Apogee Therapeutics

In other Apogee Therapeutics news, insider Carl Dambkowski sold 6,665 shares of the business’s stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $56.26, for a total value of $374,972.90. Following the completion of the transaction, the insider now owns 274,128 shares in the company, valued at $15,422,441.28. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Carl Dambkowski sold 6,665 shares of the stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $56.26, for a total value of $374,972.90. Following the completion of the sale, the insider now directly owns 274,128 shares of the company’s stock, valued at approximately $15,422,441.28. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael Thomas Henderson sold 40,000 shares of the company’s stock in a transaction that occurred on Wednesday, October 2nd. The stock was sold at an average price of $56.23, for a total value of $2,249,200.00. Following the sale, the chief executive officer now owns 1,354,487 shares of the company’s stock, valued at $76,162,804.01. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 146,665 shares of company stock valued at $7,058,635 over the last 90 days. 36.10% of the stock is owned by insiders.

Apogee Therapeutics Stock Down 1.7 %

Shares of NASDAQ:APGE opened at $54.88 on Wednesday. The stock has a market cap of $3.21 billion, a price-to-earnings ratio of -10.45 and a beta of 2.75. Apogee Therapeutics, Inc. has a 52-week low of $14.19 and a 52-week high of $72.29. The business has a 50-day moving average price of $51.04 and a 200-day moving average price of $48.66.

Apogee Therapeutics (NASDAQ:APGE) last issued its quarterly earnings results on Monday, August 12th. The company reported ($0.60) EPS for the quarter, hitting the consensus estimate of ($0.60). As a group, equities analysts anticipate that Apogee Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.